ADAR1 Capital Management’s VistaGen Therapeutics VTGN Stock Holding History

ADAR1 Capital Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$79.4K	Sell	351,141 -400,000	-53%	-$241K	﹤0.01%	266
2026 Q1	$429K	Buy	751,141 +127,566	+20%	+$77.5K	0.03%	214
2025 Q4	$413K	Buy	623,575 +510,513	+452%	+$1.84M	0.03%	198
2025 Q3	$401K	Sell	113,062 -307,703	-73%	-$919K	0.04%	150
2025 Q2	$842K	Hold	420,765	–	–	0.13%	96
2025 Q1	$1.05M	Buy	420,765 +299,304	+246%	+$847K	0.2%	79
2024 Q4	$358K	Sell	121,461 -41,617	-26%	-$117K	0.07%	129
2024 Q3	$491K	Buy	+163,078	New	+$556K	0.08%	118
2024 Q2	–	Sell	-89,938	Closed	-$475K	–	316
2024 Q1	$475K	Sell	89,938 -155,564	-63%	-$748K	0.11%	85
2023 Q4	$1.26M	Buy	+245,502	New	+$929K	0.45%	38

Other funds holding VTGN

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ADAR1 Capital Management's VTGN Position: Q2 2026 in Review

ADAR1 Capital Management reduced its VistaGen Therapeutics (VTGN) stake by 53% in Q2 2026, selling an estimated $241K and leaving 351,141 shares worth $79.4K. The position accounts for ﹤0.01% of the portfolio, ranked #266.

ADAR1 Capital Management first reported a position in VTGN in Q4 2023 and has held it in 10 quarters since. The position peaked at $1.26M in Q4 2023. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

ADAR1 Capital Management held 351,141 shares of VistaGen Therapeutics worth $79.4K as of Q2 2026.
ADAR1 Capital Management sold 400,000 VistaGen Therapeutics shares in Q2 2026, an estimated $241K.
VistaGen Therapeutics made up ﹤0.01% of ADAR1 Capital Management's portfolio in Q2 2026, its #266 holding.
ADAR1 Capital Management first reported a position in VistaGen Therapeutics in Q4 2023 and has held it in 10 quarters since.
ADAR1 Capital Management's VistaGen Therapeutics position peaked at $1.26M in Q4 2023.
48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.